References
- Kenakin TP. Prenalterol as a selective cardiostimulant: differences between organ and receptor selectivity. J Cardiovasc Pharmacol. 1985;1985:208–210.
- Rook JM, †∥, Bertron JL, Cho HP, et al. A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity. ACS Chem Neurosci. 2018;9:2274–2285.
- Kenakin TP, Cook DA. Blockade of histamine-induced contractions of guinea pig ielum by beta-haloalkylamines. Can J Physiol Pharmacol. 1976;54:386–392.
- Unett DJ, Gatlin J, Anthony TL, et al. Kinetics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and duration. J Pharmacol Exp Ther. 2013;347:645–659.
- Stockton JM, Birdsall NJ, Burgen AS, et al. Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol. 1983;23:551–557.
- Ehlert FJ. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol. 1988;33:187–194.
- Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci. 1983;220:141–162.
- Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov. 2005;4:919–927.
- Ehlert FJ. Analysis of allosterism in functional assays. J Pharmacol Exp Ther. 2005;315:740–754.
- Price MR, Baillie GL, Thomas A, et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005;68:1484–1495.
- Ma L, Seager MA, Wittmann M, et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. PNAS. 2009;106:15950–15955.
- Mistry SN, Jörg M, Lim H, et al. 4-Phenylpyridin-2-one derivatives: a novel class of positive allosteric modulator of the M1 muscarinic acetylcholine receptor. J Med Chem. 2016;59:388–409.
- Stahl E, Elmslie G, Ellis J. Allosteric modulation of the M3 muscarinic receptor by amiodarone and N-ethylamiodarone: application of the four-ligand allosteric two-state model. Mol Pharmacol. 2011;80:378–388.
- Berizzi AE, Gentry PR, Rueda P, et al. Molecular mechanisms of action of M5 muscarinic acetylcholine receptor allosteric modulators. Mol Pharmacol. 2016;90:427–436.
- Bdioui S, Verdi J, Pierre N, et al. Equilibrium assays are required to accurately characterize the activity profiles of drugs modulating Gq-coupled GPCRs. Mol Pharmacol. 2018;94:992.
- Trinquet E, Bouhelal R, Dietz M. Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-one assay. Expert Opin Drug Discov. 2011;6:981–994.
- Trinquet E, Fink M, Bazin H, et al. D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal Biochem. 2006;358:126–135.